BeCytes Biotechnologies
- Company typePrivate
- Founded2015
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
BeCytes Biotechnologies firmographics
Firmographics- Name
- BeCytes Biotechnologies
- Legal name
- Cytes Biotechnologies S.L.
- Website
- https://becytes.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BeCytes Biotechnologies industry classification
Industry- Product category
- Primary Liver Cell Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where BeCytes Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
BeCytes Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Primary Liver Cell Products: Sale of fresh, cryopreserved, and plateable human and animal hepatic cells including primary human hepatocytes, suspension hepatocytes, and non-parenchymal cells.
- Tissue Sourcing Services: Platform for coordinating human tissue donation for biomedical research, managing the entire process from donor selection to tissue delivery.
- Preclinical CRO Services: Scientific and technological guidance plus preclinical investigations for validation of novel technologies and healthcare items in development.
- Culture Media Products: Sale of thawing, plating, and maintenance media required for hepatocyte culture and research processes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Custom quote-based pricing for primary liver cells and services |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
BeCytes Biotechnologies product offering
Product offeringCore offering
BeCytes Biotechnologies supplies primary human and animal liver cells—including fresh, cryopreserved, plateable, and suspension hepatocytes, plus non-parenchymal cells—and complements these biological products with ISBER-compliant human tissue sourcing coordination and preclinical CRO services for drug discovery and hepatotoxicity research. Products are delivered with comprehensive certificates of analysis covering donor demographics, viability (post-thaw viability above 85%), enzyme expression, and 3D spheroid formation capability.
Product overview
BeCytes Biotechnologies is a specialized provider of primary liver cells and tissue sourcing services for biomedical research. The portfolio centers on primary human hepatocytes (fresh, cryopreserved, plateable, and suspension formats) with over 85% post-thaw viability, supplemented by non-parenchymal cells (Kupffer Cells, Liver Sinusoidal Endothelial Cells, Stellate Cells) available from single donors. The company also offers animal hepatocytes across multiple species, culture media for all cell types, tissue sourcing coordination following ISBER Guidelines, and preclinical CRO services. Products are supplied with comprehensive certificate of analysis including donor demographics, viability data, morphology, spheroid formation capability, and cytochrome P450 induction characterization.
Differentiator
Problem solved
Functional benefit
Products and services
- Primary Fresh Human Hepatocytes Fresh primary human hepatocytes isolated from liver tissue unsuitable for transplantation, supplied in suspension (HuHEFS) or plated formats (HuHEFPN, HuHEFPO). Retain essential metabolic activities, drug-metabolizing enzymes, and transporters; intended for in vitro metabolism, toxicity, and drug-drug interaction studies by preclinical research scientists.
- Plateable Primary Human Hepatocytes (Cryopreserved) Cryopreserved plateable human hepatocytes qualified to maintain a confluent monolayer (85% confluency) for at least five days. Available in variants including HuHECP (standard), HuHECP-30 (3D certified), HuHECPMI (metabolism and induction certified), and HuHECPMI-3D (metabolism, induction certified, and 3D qualified). Sold to preclinical research customers needing reproducible plateable hepatocytes.
- Human Suspension Hepatocytes Cryopreserved human hepatocytes cultured in suspension (product code HuHECS) ideal for short-term studies of two to eight hours investigating immediate compound responses, metabolic pathways, and detoxification processes. Sold to ADME/DMPK and drug metabolism researchers.
- Pathological Hepatocytes (MASLD/MASH) Primary human hepatocytes sourced from MASLD/MASH-diagnosed donors (product code HuHECSM) for studying liver disease progression in suspension format, metabolism certified and MASH diagnosed. Targeted at researchers studying metabolic dysfunction-associated steatohepatitis and related liver diseases.
- Primary Human Non-Parenchymal Cells (NPCs) Liver non-parenchymal cells including Kupffer cells, liver sinusoidal endothelial cells (LSECs/LECs), and hepatic stellate cells, supplied individually or as mixed populations from single donors. Used by researchers building co-culture and 3D liver models that more faithfully recreate hepatic physiology.
- Animal Cells Primary hepatocytes and subcellular liver fractions from animal species including beagle, cynomolgus monkey, minipig, horse, sheep, chicken, duck, fish, and rodents, supplied for preclinical research programs requiring species-specific hepatic models.
- Culture Media Complete media portfolio including thawing, plating, and maintenance media for hepatocyte culture, plus specific LSEC media and 3D spheroid formation media for advanced liver models. Sold to researchers using BeCytes hepatocytes and NPCs in culture.
- Tissue Sourcing Service Service platform that coordinates human tissue donation for biomedical research following ISBER Guidelines and local/international regulations. Manages the entire process from donor selection and IRB submission through ethical compliance and end-to-end procurement, offered to pharmaceutical, biotech, and academic research customers.
- Preclinical CRO Service Contract research organization offering scientific and technological guidance plus preclinical investigations for the validation of novel technologies and healthcare items under development. Provided to pharmaceutical and biotech customers running preclinical programs.
Quantifiable outcome
- Post-thawing viability superior to 85%
- +2 more outcomes
Companies that use BeCytes Biotechnologies
Customer profileSegments2 records
Ideal customer profiles2 records
BeCytes Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BeCytes Biotechnologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BioIVTcoreBeCytes was acquired by BioIVT in 2025, expanding global access to ethically sourced human biospecimens for research. The acquisition integrates BeCytes into BioIVT's portfolio, with BeCytes operating under BioIVT's branding and systems while maintaining its product offerings and scientific expertise.
- Institute for Bioengineering of Catalonia (IBEC)coreCollaboration with IBEC's Biosensors for Bioengineering group led by Javier Ramón on the Nuclis I+D project 'Generation of new 3D models of microencapsulated liver cell pools by bioprinting'. The project aims to create cutting-edge 3D in vitro human liver models using diverse human hepatic cells through bioprinting technology.
- Hospital NetworkcoreExtensive network of hospitals for obtaining human liver tissue for research purposes. Cytes collaborates with clinical sites to implement tissue sourcing projects, coordinating protocol preparation, IRB submission, and ethical compliance.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
BeCytes Biotechnologies competitors and assessment
Company assessmentDirect peers
- CellGenix: CellGenix manufactures primary cells and cell culture reagents for cell therapy and translational research, providing primary hepatocytes and supporting media comparable to BeCytes' portfolio.
- Thermo Fisher Scientific (Gibco / CellzDirect): Thermo Fisher's Gibco and CellzDirect brands offer primary human hepatocytes, non-parenchymal cells, and culture media used across the same drug metabolism and toxicology workflows that BeCytes serves.
- Sekisui XenoTech: Sekisui XenoTech specializes in primary hepatocytes, subcellular liver fractions, and ADME/DMPK services. It is one of the closest direct competitors to BeCytes in both products and preclinical liver services.
- Lonza Bioscience (Walkersville): Lonza's Walkersville site is one of the largest global suppliers of primary human hepatocytes, plateable and cryopreserved, for ADME/toxicology research. It directly competes with BeCytes' core product lines and targets the same pharma preclinical customers.
Emerging players
- Emulate: Emulate's Liver-Chip is a microphysiological system for liver disease modeling and toxicology, competing in the human-relevant in vitro liver model space where BeCytes supplies primary hepatocytes and 3D products.
- InSphero: InSphero develops 3D liver microtissues and spheroid models for drug safety and efficacy testing, overlapping with BeCytes' 3D spheroid-certified hepatocytes and culture media for advanced in vitro liver models.
Broad incumbents
- BioIVT: BioIVT is now BeCytes' parent company, but it also sells human hepatocytes, liver tissue, and biospecimens through its own catalog, overlapping with BeCytes' offerings and serving the same pharma customer base at a larger scale.
- Corning Life Sciences (Hepatocyte Products): Corning supplies primary hepatocytes and ultra-low attachment plates commonly used in 3D spheroid formation, directly overlapping with BeCytes' plateable hepatocytes, 3D-certified products, and supporting culture media.
Regional players
- Pelobiotech: Pelobiotech supplies primary human hepatocytes, non-parenchymal liver cells, and specialized media across Europe, serving many of the same academic and preclinical research customers as BeCytes.
- Cytonet: Cytonet focuses on human liver cell products and cell-based therapies in Europe, comparable to BeCytes in primary liver cell sourcing and disease-state hepatocyte supply, but with a more clinical/translational orientation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
BeCytes Biotechnologies social profiles
Digital presenceBeCytes Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
BeCytes Biotechnologies leadership team
Management profileNumber of profiles
Profiles2 records
BeCytes Biotechnologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BeCytes Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BeCytes Biotechnologies
What does BeCytes Biotechnologies do?
BeCytes Biotechnologies supplies primary human and animal liver cells—including fresh, cryopreserved, plateable, and suspension hepatocytes, plus non-parenchymal cells—and complements these biological products with ISBER-compliant human tissue sourcing coordination and preclinical CRO services for drug discovery and hepatotoxicity research. Products are delivered with comprehensive certificates of analysis covering donor demographics, viability (post-thaw viability above 85%), enzyme expression, and 3D spheroid formation capability.
Is BeCytes Biotechnologies a public or private company?
BeCytes Biotechnologies is a private company. It is classified as corporate owned and is currently acquired.
When was BeCytes Biotechnologies founded?
BeCytes Biotechnologies was founded in 2015. It employs 11 to 50 people.
Where is BeCytes Biotechnologies based?
BeCytes Biotechnologies is headquartered in Barcelona, Spain, in the Europe region.
How does BeCytes Biotechnologies make money?
Four revenue lines are on record. Primary Liver Cell Products are the primary driver. The others are tissue Sourcing Services, preclinical CRO Services and culture Media Products.
Who are BeCytes Biotechnologies's main competitors?
Direct peers on record are CellGenix, Thermo Fisher Scientific (Gibco / CellzDirect), Sekisui XenoTech and Lonza Bioscience (Walkersville). Emerging players are Emulate and InSphero. Broad incumbents are BioIVT and Corning Life Sciences (Hepatocyte Products). Regional players are Pelobiotech and Cytonet.
Does BeCytes Biotechnologies have an API?
No public API is recorded for BeCytes Biotechnologies.
What industry is BeCytes Biotechnologies in?
BeCytes Biotechnologies's product category is Primary Liver Cell Products. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 325414 and its SIC code is 2836.